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PREFACE 
My passion for public health developed first from a desire to understand more about 
the context of medicine – we do not practice medicine in a vacuum, and so to consider 
medicine only from a physiological point of view is absurd. By taking interest in the 
denominator as well as the numerator, by looking at whole communities, large environments, 
umbrella policies, and socioeconomic barriers to healthcare, physicians can provide better 
quality care for their patients by meeting patient needs instead of physicians’ or 
administrators’ needs. Medicine and the need for patient advocates within medicine becomes 
powerfully relevant when viewed through the lens of public health. This project, specifically, 
grew out of an evident need for patients to have higher quality follow-up referral after 
discharge from the Emergency Department (ED), to receive a “warm handoff” in the words 
of one my mentors, instead of a cold or absent one. My hope is that this work can be used to 
improve the quality of patient referrals made in the ED. 
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ABSTRACT 
Background: One strategy to decrease uncontrolled hypertension is to increase 
follow-up with primary care after diagnosis of asymptomatic hypertension in the Emergency 
Department (ED). To improve such interventions, this study identified risk factors of non-
adherence among individuals 18-60 years old with a diagnosis of asymptomatic hypertension 
in the ED and access to care. 
Methods: Data was obtained from the IBM® MarketScan® Commercial Database 
between January 2012 and September 2015. Rates of non-adherence to follow-up was 
determined for individuals discharged from the ED with a primary diagnosis of essential 
hypertension. Multivariate logistic regression was used to calculate adjusted odds ratios. 
Demographic and structural variables were evaluated to determine their relationship with 
non-adherence to follow-up. 
Results: Two-thirds of the study population did not adhere to follow-up within 30 
days. Risk factors for non-adherence included no history of recent visit with primary care 
(OR=1.87; 95% CI=1.81-1.93) and multiple prior ED visits (OR=1.65; 95% CI=1.57-1.73). 
Protective characteristics included history of filling an anti-hypertensive prescription in last 
year (OR=0.42; 95% CI=0.40-0.43); or history of filling a 30-day anti-hypertensive 
prescription on day of index event (OR=0.83; 95% CI=0.80-0.87). 
Conclusion: Individuals who have not visited primary care or who are at the ED for 
the third time in 12 months are more likely to be non-adherent to follow-up. History of filling 
a 30-day anti-hypertensive prescription within one day of index event or in prior 12 months 
is associated with increased adherence to follow-up and should be further explored as a 
strategy for encouraging follow-up in this population.  
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BACKGROUND  
Literature Review 
Hypertension in the ED. Hypertension and hypertension-related complaints in the ED are not 
only prevalent but have increased over the last decade in both the United States and 
Canada1,2. Individuals who present in the ED with hypertension, defined for individuals 
under 60 years of age by the Eighth Report of the Joint National Committee (JNC 8) to be 
blood pressure greater than or equal to 140 mm Hg systolic or greater than or equal to 90 mm 
Hg diastolic3, can be loosely categorized into three groups: those who have incidental high 
blood pressure findings unrelated to the chief complaint and are left undiagnosed, those who 
have high blood pressure diagnosed in the ED but do not exhibit acute symptoms of 
hypertension-related end-organ damage and are subsequently discharged for follow-up with 
primary care, and those with a chief complaint that may or may not be hypertension but who 
are experiencing acute hypertension-related end-organ damage.  
 
The first of these groups, and perhaps the largest proportion of individuals, are left 
undiagnosed and therefore cannot be studied with a claims dataset4,5. The last of these 
groups, clearly not asymptomatic, requires emergent admittance to the hospital for treatment. 
However, the second group represents individuals at risk for falling into the population of 
hypertensive adults described previously, who have uncontrolled hypertension, a diagnosis, 
and, if they have insurance, access to care. Interestingly, despite decreases in hospitalization 
of hypertensive patients in the ED from 2006 to 2012, ED visits with a primary diagnosis of 
hypertension increased 4.4% each year and comprised about 1% of all adult ED visits2. It can 
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be inferred, then, that relatively more individuals are falling into this second group of 
individuals who are diagnosed with asymptomatic hypertension and discharged from the ED. 
This group of individuals is the subject of interest for this study. 
 
Hypertensive individuals without acute end-organ damage discharged from the ED with or 
without treatment or a prescription for antihypertensive medication have an overall low-risk 
of short-term risk of complications1,6,7. Guidelines suggest the discharging physician can 
decide whether to prescribe antihypertensive medication, to refer to a Primary Care Physician 
(PCP), or to do both. Recent literature goes further to suggest that emergency physicians do 
have a role in screening for hypertension, in actively encouraging follow-up after an ED visit 
by securing a follow-up appointment or contacting patients’ PCPs, and in using clinical 
judgment to determine when prescribing antihypertensive medication is appropriate8-11.  
 
Adherence to follow-up after ED diagnosis. Hypertension remains untreated if an individual 
is referred to primary care and cannot attain follow-up, and the inaccessibility of primary 
care has been proposed as an important factor in increased ED use12. Additionally, studies on 
timely follow-up after referral from the ED have found that follow-up within a week is 
difficult to achieve, perhaps even for those with private insurance13,14. Barriers to timely 
follow-up may include race, socioeconomic status, age, history of mental illness, living 
environment, insurance status, PCP status, and access to the healthcare system11. In this 
study, all individuals have presumed access to the healthcare system through commercial 
insurance.  
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The dependent variable examined in this study is adherence to follow-up with a PCP after 
ED discharge. Interventions to increase successful follow-up after referral from the ED have 
been attempted, with varying levels of success. However, it remains unclear whether one or 
another method is better for increasing care coordination across more than one ED15. A better 
understanding of the risk factors of non-adherence to follow-up after referral from the ED 
may help to improve intervention efforts in the future and improve hypertension control 
among the insured, nonelderly population.  
 
Variables of nonadherence in the literature. Prescription nonadherence has been associated 
with use of the ED for hypertensive management in minority populations16, but the 
relationship between prescription nonadherence and using the ED for hypertensive 
management or prescription nonadherence and nonadherence to follow-up has not been 
described for a national, commercially insured population. In an attempt to understand this 
relationship, this study measures prescription adherence for individuals who have a history of 
hypertension prescription fills in the 12 months prior to the initial ED visit. 
 
Other demographic variables may also have a role in nonadherence to follow-up. Age, 
specifically, may play a role in hypertension control as adults aged 18-39 have lower rates of 
awareness, treatment, and control compared with older adults17. Barriers related to race, 
history of mental illness, or the living environment are not supported by this database. 
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Public Health Significance 
Cardiovascular disease kills more people worldwide than any other cause of death, making 
the risk factors for cardiovascular disease, including uncontrolled hypertension, a high 
priority for interventional public health and preventive medicine18 . The prevalence of 
hypertension in the United States, as mentioned previously, is significant. According to the 
National Health and Nutrition Examination Survey for the years 2005-2008, 68 million 
adults aged 18 years or older had hypertension. Over 50% of hypertensive adults had 
uncontrolled hypertension, and of these, over 80% were aware of their diagnosis19. 
Hypertension is associated with overall shorter life expectancy, and from 2000 to 2010 the 
death rate attributable to high blood pressure increased by 16%20. In addition to the negative 
consequences of increased blood pressure on cardiovascular health, hypertension in the U.S. 
is also a source of health disparity. Of great concern are the disparities in prevalence and/or 
control among non- Hispanic blacks, women, and Mexican-Americans21-24.  
 
The monetary cost of hypertension is also significant. The 2010 estimated direct and indirect 
cost of hypertension was $46.4 billion, and the direct and indirect cost of cardiovascular 
disease and stroke is estimated to be $315.4 billion20. Because chronic disease management 
with continuity of care is associated with fewer ED visits and lower costs25, hypertension 
management at the level of the PCP is important. Similarly, because emergency care for 
nonurgent conditions costs more than care in other settings26, asymptomatic hypertension is 
more cost-efficiently treated in primary care settings. The increasing number of emergency 
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department visits and subsequent overcrowding of the ED is another incentive for keeping 
patients out of the ED and in a primary care setting27,28. 
 
With a greater emphasis being placed on primary care prevention to decrease healthcare costs 
associated with preventable adverse events, the connection between emergency management 
of asymptomatic hypertension and primary care follow-up needs to be better understood. 
Risk factors identified in this study will allow for more targeted interventions in the insured, 
nonelderly population to increase follow-up and, presumably, to increase likelihood of 
hypertension control for those who have uncontrolled hypertension due to lack of proper 
care. The association between ED visits for asymptomatic hypertension and follow-up 
appointments with a PCP has not been studied. Additionally, adherence rates for follow-up 
visits after any ED diagnosis for both nonelderly and commercially insured populations is 
underrepresented in the literature. 
 
Specific Aims 
The first aim of this project is to determine the rate of follow-up with primary care after a 
diagnosis of asymptomatic hypertension in the ED for those with commercial insurance. 
Follow-up is expected to be less than 100%. The second aim of this project is to explore 
predictors of non-adherence to follow-up by analyzing the relationship between non-
adherence and several demographic and structural variables with multivariate logistic 
regression. 
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JOURNAL ARTICLE 
Title: Non-adherence to follow-up after asymptomatic hypertension in the Emergency 
Department  
Proposed Journal: American Journal of Emergency Medicine 
  
I. Introduction 
Hypertension (HTN) is one of the leading risk factors affecting global burden of disease and 
mortality29,30. Despite recent improvements in treatment and control, over 50% of 
hypertensive adults still suffer from uncontrolled HTN. Of those with uncontrolled HTN, 
over 50% are aware of their diagnosis, and 85% have health insurance31. Novel strategies are 
needed to improve HTN control32. Recently, Emergency Department (ED) visits with a 
primary diagnosis of HTN, both with and without hospitalization, have increased, 
highlighting the ED as an appropriate setting for pursuit of better HTN education, referral to 
primary care, and improved adherence to follow-up1,2,33,34. A recent study found emergency 
physicians are unable to predict which patients are at higher risk of non-adherence to follow-
up with primary care35, and it remains unclear which interventions increase follow-up after 
referrals15. Furthermore, adherence to follow-up after ED discharge has not been studied in 
association with anti-hypertensive prescription history.  
 
A better understanding of the risk factors for non-adherence may improve interventions in 
the future and ultimately aid in reducing uncontrolled HTN for those with a known diagnosis 
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and access to care. This retrospective cohort study sought to identify demographic and 
structural predictors of non-adherence to follow-up with primary care after primary diagnosis 
of asymptomatic Essential HTN in the ED. Non-elderly adults, in particular, were studied 
because increased control of hypertension in a non-elderly population would lead to 
increased long-term morbidity and mortality benefits compared to older cohorts.  
 
II. Methods 
Data source. The study population was derived from the IBM MarketScan® Commercial 
Database1, a national convenience sample of commercially insured individuals, representing 
data from large employers, as well as medium and small firms36. The database includes 
claims submitted by any provider who saw a covered individual, including in-network 
providers, out-of-network providers, and visits denied for payment. Use of this database has 
precedent in the literature and is fully compliant with the Healthcare Information Portability 
and Accountability Act (HIPAA)37. The study was reviewed by the UT Houston Health 
Science Center Review Board and deemed to be exempt. 
 
Study population. This was a retrospective cohort study of commercially insured non-elderly 
adults identified within the MarketScan database from 1 January 2012 through 30 September 
2015. Diagnosis was based on International Classification of Diseases (ICD) -Revision 9 
codes for Essential (Primary) HTN (401.1 and 401.9). Individuals included in the study were 
aged 18-60 years at time of index event, were discharged from the ED without same-day 
                                               
1 MarketScan is a registered trademark of IBM Corporation in the United States, other countries or both. 
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admission to the hospital, were not admitted to an inpatient setting within seven days of 
index event and were enrolled with insurance for at least two continuous months during the 
year of the index event (see Figure 1). Inclusion criteria also required having prescription 
benefit information available through the database. Total data analyzed spanned 12 months 
before each index event through follow-up, defined as up to 30 days after index event. 
 
Study definitions. Index event was defined as the first ED visit billed with a primary 
diagnosis of essential hypertension (ICD 9 codes 401.1 and 401.9) without same-day 
admission. The primary outcome, non-adherence to follow-up with primary care, was defined 
as absence of a visit with family medicine, internal medicine, cardiology, geriatrics, nurse 
practitioners (NP) or physician’s assistants (PA) within 30 days of index event. Of note, the 
database does not include specialty information for NPs or PAs, but it was assumed that a 
visit for primary diagnosis HTN with a NP or a PA would have occurred in one of the 
previously defined primary care settings. This is referred to as the “combined analysis.” In 
this analysis, individuals with a primary care visit were excluded if the billing was based on a 
non-HTN primary diagnosis. While the primary diagnosis for a follow-up of uncontrolled 
blood pressure would ideally be “HTN,” individuals with multiple comorbidities may have 
been billed for another diagnosis, which took priority for the follow-up visit. Any contact 
with primary care after discharge from the ED is clinically relevant because checking blood 
pressure is standard of care for most visits, and hypertensive blood pressure findings would 
likely be addressed during the encounter. Although if the primary diagnosis was not HTN, it 
is unclear whether or not the blood pressure or recent ED visit was addressed at the follow-up 
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visit, these visits are relevant as a sensitivity analysis. Individuals in the sensitivity analysis 
included all primary care visits within 30 days of the index event, regardless of diagnosis. 
Both the primary and sensitivity analyses are included in this report.  
 
Thirty days was chosen to represent adherence given existing literature which suggests 
obtaining follow-up within one week might be an unreasonable expectation for obtaining 
primary care follow-up after an ED visit in the United States, even for those with commercial 
insurance13,14.   
 
Demographics and characteristics. Explanatory variables included age and sex (with male as 
reference), employment status of policy holder, dichotomized into full-time employment or 
“other”; continuous insurance coverage, defined as coverage for continuous 12 months 
during year of index event, or non-continuous; and type of insurance benefit plan, 
dichotomized into PPO or “other.” 
 
Structural variables were included to explore the effects of an individual’s interaction with 
the medical system prior to and on the day of index event. First, the variable “Not 
Established with Primary Care” was determined by selecting individuals who were not billed 
for any visit during the 12 months prior to the index event with a primary care. Second, 
individuals were identified as “ED High Utilizer” if they had two or more visits to the ED for 
any diagnosis in the 12 months prior to index event, plus the index event, for a total of three 
visits within 12 months. Third, the variable “Inpatient Admission in Prior 90 Days” was 
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determined by selecting individuals who had at least one inpatient admission in the 90 days 
prior to the index event.  
 
Finally, two pharmaceutical variables were identified. The first variable, ED Prescription, 
identified individuals who filled a 30-day prescription of an anti-hypertensive medication on 
the day of index event (day 0) or next day (day 1), likely indicative of prescription by an ED 
physician, NPs, or PAs. When prescription fill date occurred on Day 1 and follow-up visit 
also occurred on Day 1, then the individual was excluded from the model to avoid 
confounding results due to PCP prescription of anti-hypertensives. Prescriptions filled after 
Day 1 could not reasonably be assumed to have been written in the ED, and prescriptions for 
days-supply other than 30 days were not included because these time frames did not fit the 
research question. The second pharmaceutical variable described individuals who filled an 
anti-hypertensive medication in the 12 months prior to index event. Anti-hypertensives 
included ACE inhibitors, alpha-beta blockers, beta blockers, calcium channel blockers, loop 
diuretics, potassium-sparing diuretics, thiazides, and vasodilating agents. Angiotensin-
receptor blockers were not included in the analysis due to limitations of the Marketscan 
database. Prescription data from this database includes mail order prescriptions and specialty 
pharmacies36. 
 
Statistical analysis. Unadjusted differences between adherent and non-adherent groups were 
determined by t-tests for the continuous variable and by chi square tests for categorical 
variables. Logistic regression was used to evaluate the impact of the explanatory variables on 
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non-adherence to follow-up, adjusting for all risk factors. Random split-sample cross-
validation was used to assess the validity of the model in the primary analysis. Akaike and 
Bayesian information criterion, as well as area under the receiver operator curve, were used 
to compare relative fit between the model developed in the training sample and the model fit 
by the validation sample. For sensitivity analysis, we examined differences between the odds 
ratios for our combined analysis and for those from the sensitivity analysis (any primary 
diagnosis). Stata 15.1 (StataCorp LLC, College Station, Texas) was used to conduct all 
analyses38.   
 
III. Results 
Characteristics of study subjects: A total of 84,929 individuals met inclusion criteria for this 
study. The study population included individuals aged 18-60 years, with a mean age of 47.3 
(SD = 9.7). A total of 57% were female, and age distribution between males and females was 
consistent. Plan and coverage information can be found in Table 1. For those who adhered to 
follow-up, primary care visits were completed with family practice (53%), internal medicine 
(33%), cardiology (10%), geriatrics (1%), or with a nurse practitioner or physician’s assistant 
(3%). Table 1 describes the characteristics of the combined analysis. There was no missing 
data in the dataset. Graph 2 shows the day of first follow-up visit for primary diagnosis HTN. 
Follow-up rate was much decreased after seven days. 
 
Main results: Overall, this study found 66% non-adherence to follow-up for HTN after 
discharge from the ED. A total of 30,448 (35.9%) individuals had no history of a PCP visit in 
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the 12 months prior to their index event. Only 4.9% of individuals had a recent inpatient 
admission, and 11.7% visited the ED two or more times in the 12 months prior to index 
event. A majority (76.1%) of individuals filled a prescription for anti-hypertensive 
medication in the 12 months prior to index event, and 13.9% filled a 30-day prescription for 
anti-hypertensive medication on the day of index event (Day 0) or next-day (Day 1). Of note, 
86.2% of those who filled a 30-day prescription for anti-hypertensives also had a history of 
filling an antihypertensive prescription in the last 12 months, and 30-day prescriptions 
represent 77% of all prescriptions filled on day 0 to 1 (see Appendix B). 
 
Table 2 shows the adjusted odds ratio for each characteristic in its relationship to non-
adherence in the combined model and cross validation models (i.e., training sample and 
validation sample). Sex and age were not significantly associated with non-adherence. 
Continuous coverage and PPO-type insurance were statistically significant. Other significant 
risk factors for non-adherence to follow-up included no history of PCP visit in the prior 12 
months (adj. OR=1.81; 95% CI=1.76-1.86), being a high-utilizer of the ED (adj. OR=1.63; 
95% CI=1.56-1.71), and history of inpatient admission in the prior three months (adj. 
OR=1.36; 95% CI=1.28-1.46). Protective characteristics included history of filling a 30-day 
prescription for anti-hypertensives on Day 0-1 (adj. OR=0.81; 95% CI=0.78-0.84), history of 
filling anti-hypertensive prescriptions in the past year (adj. OR=0.42; 95% CI=0.41-0.44), 
continuous coverage (adj. OR=0.94; 95% CI=0.90-0.98) and PPO-type insurance (adj. 
OR=0.91; 95% CI=0.88-0.94]. Cross validation models included similar findings, with the 
exception of a non-significant finding for continuous coverage in the validation sample. 
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Akaike and Bayesian information criterion are included in Table 2, and area under the 
receiver operator curve (ROC) showed modest fit for each analysis. The sensitivity model, 
which included individuals with PCP follow-up for any diagnosis within 30 days, also had 
similar findings except that inpatient admission was non-significant and the variable “Not 
established with PCP” was much more significantly associated with non-adherence compared 
to the combined analysis (3.07 compared to 1.87).  The rest of the results of the sensitivity 
analysis can be found in Appendix A and are discussed in section IV. 
 
IV. Discussion 
In this study, 66% of the population did not adhere to follow-up within 30 days of an ED 
visit for hypertension. Predictors for nonadherence included no history of PCP visit in the 
prior 12 months, at least three visits to the ED within 12 months, and recent inpatient visit in 
the prior 3 months. Factors associated with adherence included filling a 30-day 
antihypertensive on day 0-1 after index event, history of filled antihypertensive in the last 12 
months, PPO-type insurance, and full-time employment. 
 
While other studies have shown that patient-reported lack of a PCP is associated with non-
adherence to ED follow-up appointments, this study looked specifically at patient history to 
show the negative association between lack of recent contact with a PCP and nonadherence 
to follow-up39,40. It is likely that lack of a PCP and/or lack of a recent PCP visit are both 
contributing factors to this finding, and future interventions should include both those 
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without a reported PCP and those who have not been in contact with a PCP in the last 12 
months. 
 
Previous research has also found that follow-up within seven days is difficult to obtain and 
recent hypertension guidelines suggest that severe asymptomatic hypertension can be 
followed up within 2-4 weeks from an initial encounter12,14,41; however, the rate of office 
visits seen in this study was much decreased after seven days, and the overall rate is 
consistent with rates in prior studies with shorter follow-up periods, indicating that extension 
of the follow-up surveillance window to 30 days after the ED visit does not result in 
increased adherence to follow-up13. It appears that the barriers to follow-up are not exclusive 
to short-term (within 7 days) follow-up but apply to long-term (within 30 days) follow-up as 
well. The rate of nonadherence in this study is also consistent with prior evidence that even 
those with commercial insurance encounter barriers to adhering to follow-up13. Interventions 
to increase adherence to follow-up should continue to focus on individuals both with and 
without insurance.  
 
Filling a 30-day anti-hypertensive prescription within one day of the index event was 
significantly associated with adherence to follow-up. Because the majority (86%) of those 
who filled this prescription had a history of filling anti-hypertensives, it is possible that these 
individuals were filling a prescription that was already on file at the pharmacy instead of a 
prescription from the ED. Regardless of whether the ED physician or a PCP prescribed the 
anti-hypertensive, it appears that for the 14% of the population who filled a prescription for 
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anti-hypertensives within one day of index event, adherence was more likely. Adherence was 
also more likely for those who filled an anti-hypertensive in the 12 months prior to the index 
event, which could be indicative of increased adherence due to familiarity with the disease or 
due to familiarity with a PCP. ED physicians should be encouraged that prescription of anti-
hypertensives increases likelihood of follow-up. This intervention may be especially useful 
when applied to those who have history of taking anti-hypertensives because, notably, 
although 76% of the population filled a prescription for anti-hypertensives in the prior 12 
months, only 14% of the population filled a prescription on day 0 or day 1 after the index 
event. This represents a large potential population for intervention. 
 
Those with three or more visits to the ED in 12 months were found to be significantly at risk 
for non-adherence to follow-up. While this represented a minority (12%) of the study 
population, ED physicians should recognize individuals on their third visit to the ED within 
12 months to be at high risk of not adhering to follow-up for a diagnosis of uncontrolled 
HTN, and these individuals may require greater interventional efforts. 
 
Recent inpatient admission was found to be a significant risk factor in the primary model but 
non-significant in the sensitivity model. This likely reflects individuals who followed up but 
had a comorbid condition that took priority over HTN in the primary diagnosis for billing. 
Recent inpatient admission does not appear to be a clinically significant risk factor for non-
adherence to follow-up. The other difference found between the combined and sensitivity 
analyses was that not seeing a PCP in the last 12 months was more significantly associated 
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with non-adherence. Like the previous difference, this is likely because the group of 
individuals with multiple comorbidities (and therefore higher likelihood of having visited 
their PCP in the prior 12 months) are included in the broadened primary outcome, and those 
that are left in the non-adherent group are more likely to be those who do not have multiple 
comorbidities and have not seen a PCP for any reason. 
 
The association between having PPO-type insurance or Full-time employment and adherence 
to follow-up is a novel finding in the ED follow-up literature. These could be important clues 
to the ED physicians on which individuals should be targeted for intervention. This study 
found no significant difference in follow-up rates based on sex, although females are known 
to be disproportionately affected by HTN and have not experienced the same improvements 
in HTN control over the last thirty years21. 
 
V. Limitations 
This study has several limitations. First, primary diagnosis of HTN was based on ICD-9 
codes in claims data, allowing the possibility of misclassification of diagnoses. This is a well-
known limitation to large claims database studies. Second, this is a descriptive study and 
does not represent causal evidence. Individuals adherent to follow-up may differ from those 
who are non-adherent in other ways not measured by this study. Specifically, due to 
limitations of the database, this study lacks individual demographic and socioeconomic 
variables that may contribute to non-adherence to follow-up, such as race, socioeconomic 
status, the living environment, and history of mental illness, and these should be examined in 
17 
 
future research11. Additionally, this database is reported to disproportionately represent the 
southern regions of the United States compared to other regions, which must be taken into 
account when interpreting the results42. Another database limitation is exclusion of visits or 
services rendered for cash in which no claim was submitted to the insurance company. 
Regarding prescription limitations, Angiotensin-Receptor Blockers (ARBs) are not included 
as a cardiac medication subgroup in the Marketscan Database and therefore cannot be 
identified separate from other cardiac medications. The authors of this study presume that 
individuals taking ARBs would have similar behavior to those taking other anti-
hypertensives included in the study. Finally, this is a national convenience sample 
representative of the non-elderly, commercially insured population, and results should not be 
generalized to the uninsured or elderly populations. More research should be conducted to 
see if these predictors also exist in other populations. 
 
VI. Conclusion 
The results of this study have several implications for emergency medicine and primary care 
interventions. First, the association between lack of history of PCP visit and non-adherence 
to follow-up may indicate that obtaining a “new-patient” visit or that obtaining a PCP visit 
after significant time without PCP contact is a limiting factor. Second, this study found 
several populations to target in future ED interventions to increase hypertension control, 
including individuals without history of a PCP visit or history of filling an anti-hypertensive 
prescription in the last year and individuals who visited the ED at least three times within 12 
months. ED physicians should also be encouraged to prescribe 30-day anti-hypertensives to 
18 
 
those with asymptomatic hypertension in the ED, especially to those who have taken anti-
hypertensives in the past, because it is associated with increased rates of follow-up with 
primary care. 
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Table 1:  Characteristics of population 
 
  Primary Analysis 
Characteristic Total (% total) n= 84,929 
Non-Adherent (%Row) 
n= 56,210 (66.2%) 
Adherent (%Row) 
n= 28,719 (33.8%) 
Age, mean; standard deviation 47.3; 9.7 46.9: 9.9 48.1; 9.4 
Female 47,970 (56.5%) 31,569 (65.8%) 16,401 (34.2%) 
Full Time Employment 49,244 (58.0%) 31,780 (64.5%) 17,464 (35.5%) 
PPO Insurance 54,105 (63.7%) 35,459 (65.5%) 18,646 (34.5%) 
Continuous Coverage1 72,347 (85.2%) 47,278 (65.4%) 25,069 (34.7%) 
Not Established with Primary Care2 30,448 (35.9%) 22,829 (75.0%) 7,619 (25.0%) 
ED High Utilizer3 9,940 (11.7%) 7,367 (74.1%) 2,573 (25.9%) 
Inpatient Admission in prior 90 days 4,134 (4.9%) 2,960 (71.6%) 1,174 (28.4%) 
Filled 30-Day Anti-HTN Rx from ED4 11,769 (13.9%) 7,278 (61.8%) 4,491 (38.2%) 
Filled Anti-HTN Rx in prior 12 months 64,632 (76.1%) 39,878 (61.7%) 24,754 (38.3%) 
 
 
1Enrolled for 12 months during year of index event 
2No history of primary care visit in past 12 months, any diagnosis 
3History of ≥2 prior ED visits in 12 months prior to ED visit, any diagnosis 
4Filled on day 0 or day 1 after index event 
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Table 2. Adjusted odds ratios of non-adherence for combined analysis and cross validation 
(training sample and validation sample) 
 
 Combined Analysis Training Sample Validation Sample 
Variable Adjusted OR [95% CI] Adjusted OR [95% CI] Adjusted OR [95% CI] 
Age 0.99 [0.99-1.00] 1.00 [0.99-1.04] 0.99 [0.99-1.00] 
Female 0.99 [0.96-1.02] 1.00 [0.96-1.00] 0.99 [0.95-1.03] 
Full time employment 0.89 [0.86-0.92] 0.87 [0.84-0.91] 0.91 [0.86-0.95] 
PPO Insurance 0.91 [0.88-0.94] 0.90 [0.86-0.94] 0.92 [0.88-0.96] 
Continuous Coverage1 0.94 [0.90-0.98] 0.89 [0.84-0.95] 0.98 [0.92-1.04] 
Not Established with Primary Care2 1.87 [1.81-1.93] 1.85 [1.77-1.94] 1.88 [1.80-1.97] 
ED High Utilizer3 1.65 [1.57-1.73] 1.64 [1.53-1.76] 1.66 [1.55-1.78] 
Inpatient Admission in prior 90 days 1.36 [1.26-1.46] 1.44 [1.30-1.59] 1.28 [1.16-1.41] 
Filled 30-Day Anti-HTN Rx from ED4 0.83 [0.80-0.87] 0.81 [0.76-0.86] 0.85 [0.80-0.90] 
Filled Anti-HTN Rx in prior 12 months 0.42 [0.40-0.43] 0.41 [0.39-0.44] 0.42 [0.40-0.45] 
Goodness-of-fit tests5:    
AIC - 52001.69 51882.38 
BIC - 52096.91 51977.60 
ROC 0.6372 0.6388 0.6359 
 
 
1Enrolled for 12 months during year of index event 
2No history of primary care visit in past 12 months, any diagnosis 
3History of ≥2 prior ED visits in 12 months prior to ED visit, any diagnosis 
4Filled on day 0 or day 1 after index event 
5Key: Akaike Information Criterion (AIC); Bayesian Information Criterion (BIC); Area under the Receiver Operating Curve (ROC) 
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Figure 1:  Inclusion criteria for combined and cross validation analyses, derived from IBM® 
MarketScan® Commercial Database  
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Figure 2. Days until first follow-up visit, primary diagnosis HTN 
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CONCLUSION 
The purpose of this study was to better understand the population who is non-
adherent to follow-up after diagnosis of hypertension in the ED, and the findings of this study 
have implications for both emergency medicine and primary care. Specifically, several 
predictors of non-adherence and associations with adherence were found which can guide 
future interventions in the ED and in primary care to increase the quality of referral to 
primary care. Future research is needed to understand if the predictors identified in this study 
apply to uninsured populations because if prescription of anti-hypertensives increases 
adherence to follow-up in both insured and uninsured populations, then current guidelines for 
emergency providers should be reconsidered. Additionally, claims data cannot provide 
insight on the “why” behind non-adherence to follow-up, and further research is also needed 
to better understand barriers to achieving follow-up among the non-elderly, commercially 
insured population.  
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APPENDICES 
Appendix A:  Characteristics and adjusted odds ratios of non-adherence, side-by-side 
comparison of non-adherence for combined and sensitivity analyses 
 
 
 
1Enrolled for 12 months during year of index event 
2No history of primary care visit in past 12 months, any diagnosis 
3History of ≥2 prior ED visits in 12 months prior to ED visit, any diagnosis 
4Filled on day 0 or day 1 after index event 
5Key: Akaike Information Criterion (AIC); Bayesian Information Criterion (BIC); Area under the Receiver Operating Curve (ROC) 
 
 
 
 
 
 
  Combined Analysis Sensitivity Analysis Combined Analysis Sensitivity Analysis 
 Total (% total) n= 84,929 
Non-Adherent 
(%Row) 
n= 56,210 (66.2%) 
Non-Adherent 
(%Row) 
n= 37,292 (43.9%) 
Adjusted OR [95% 
CI] Adjusted OR [95% CI] 
Characteristic      
Age, mean; standard deviation 47.3; 9.7 46.9: 9.9 46.3; 10.0 0.99 [0.99-1.00] 0.99 [0.99-0.99] 
Female 47,970 (56.5%) 31,569 (65.8%) 20,571 (42.9%) 0.99 [0.96-1.02] 0.98 [0.95-1.01] 
Full Time Employment 49,244 (58.0%) 31,780 (64.5%) 20,419 (41.5%) 0.89 [0.86-0.92] 0.84 [0.82-0.86] 
PPO Insurance 54,105 (63.7%) 35,459 (65.5%) 23,167 (42.8%) 0.91 [0.88-0.94] 0.87 [0.85-0.90] 
Continuous Coverage1 72,347 (85.2%) 47,278 (65.4%) 30,934 (42.8%) 0.94 [0.90-0.98] 0.96 [0.92-1.00] 
Not Established with Primary 
Care2 30,448 (35.9%) 22,829 (75.0%) 18,818 (61.8%) 1.87 [1.81-1.93] 3.07 [2.98-3.17] 
ED High Utilizer3 9,940 (11.7%) 7,367 (74.1%) 4,761 (47.9%) 1.42 [1.57-1.73] 1.42 [1.36-1.49] 
Inpatient Admission in prior 90 
days 4,134 (4.9%) 2,960 (71.6%) 1,767 (42.7%) 1.36 [1.26-1.46] 1.06 [0.99-1.13] 
Filled 30-Day Anti-HTN Rx from 
ED4 11,769 (13.9%) 7,278 (61.8%) 5,056 (43.0%) 0.83 [0.80-0.87] 0.92 [0.89-0.96] 
Filled Anti-HTN Rx in prior 12 
months 64,632 (76.1%) 39,878 (61.7%) 25,430 (39.4%) 0.42 [0.40-0.43] 0.50 [0.48-0.52] 
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Appendix B: Days-supply for prescriptions filled on day 0 or day 1 after ED visit 
 
 
 
 
 
Appendix C: Regional Distribution of Individuals
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